A Study on the Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes Combined With Metabolic-associated Fatty Liver Disease and Its Molecular Mechanisms
To evaluate the effects of subcutaneous injection of semaglutide for 12 weeks on patients with type 2 diabetes mellitus (T2DM), compared with concurrent energy-restricted management, on glycemic control, weight loss, inflammatory markers, liver fat content, and other parameters. The study also observed the subcutaneous and visceral fat of the participants and explored the molecular mechanisms of action, providing high-quality evidence-based support for the timing and targets of intervention in this population.
• Age 18-75 years;
• BMI≥25 kg/m²;
• Diagnosed as type 2 diabetes mellitus patients according to the Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2020 Edition);
• HbA1c≤8.5%;
• Duration of diabetes ≤3 months, and no use of antihyperglycemic drugs;
• Willing to participate in this study, and after full informed consent, agrees to strictly follow the treatment plan and promises to attend follow-up visits on time, and signs the informed consent form.